申请人:Nivalis Therapeutics, Inc.
公开号:US20170281612A1
公开(公告)日:2017-10-05
The present invention is directed to a method of treating or lessening the severity of cystic fibrosis in a patient, comprising the step of administering to said patient an effective amount of an inhibitor of S-nitrosoglutathione reductase (GSNOR) in combination with one or more secondary active agents.